Business Description
Bioceltix SA
ISIN : PLBCLTX00019
Description
Bioceltix SA develops therapies for veterinary use that harness the immunomodulatory properties of mesenchymal stem cells. Its pipeline products include BCX-CM-J for Degenerative joint lesions; BCX-CM-S for Autoimmune and inflammatory diseases in dogs; BCX-EM for Tendon damage and BCX-FM for Gingivostomatitis.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 40.3 | |||||
| Equity-to-Asset | 0.93 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -73.4 | |||||
| 3-Year EPS without NRI Growth Rate | -54.4 | |||||
| 3-Year FCF Growth Rate | -96.2 | |||||
| 3-Year Book Growth Rate | 35.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 28.49 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 91.32 | |||||
| 9-Day RSI | 82.43 | |||||
| 14-Day RSI | 75.75 | |||||
| 6-1 Month Momentum % | 23.57 | |||||
| 12-1 Month Momentum % | -15.28 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 15.5 | |||||
| Quick Ratio | 15.5 | |||||
| Cash Ratio | 14.21 | |||||
| Days Inventory | 2.38 | |||||
| Days Payable | 527.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.9 | |||||
| Shareholder Yield % | -10.19 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -66.71 | |||||
| ROA % | -57.7 | |||||
| ROIC % | -172.05 | |||||
| ROC (Joel Greenblatt) % | -783.18 | |||||
| ROCE % | -65.49 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 10.2 | |||||
| Price-to-Tangible-Book | 10.46 | |||||
| EV-to-EBIT | -25.6 | |||||
| EV-to-EBITDA | -26.42 | |||||
| EV-to-FCF | -20.83 | |||||
| Price-to-Net-Current-Asset-Value | 11.2 | |||||
| Price-to-Net-Cash | 12.29 | |||||
| Earnings Yield (Greenblatt) % | -3.91 | |||||
| FCF Yield % | -4.27 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bioceltix SA Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil zł) | |||
| EPS (TTM) (zł) | -3.78 | ||
| Beta | 0.76 | ||
| Volatility % | 49.66 | ||
| 14-Day RSI | 75.75 | ||
| 14-Day ATR (zł) | 2.834567 | ||
| 20-Day SMA (zł) | 79.09 | ||
| 12-1 Month Momentum % | -15.28 | ||
| 52-Week Range (zł) | 58.9 - 98 | ||
| Shares Outstanding (Mil) | 4.92 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bioceltix SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bioceltix SA Stock Events
| Event | Date | Price(zł) | ||
|---|---|---|---|---|
| No Event Data | ||||
Bioceltix SA Frequently Asked Questions
What is Bioceltix SA(WAR:BCX)'s stock price today?
The current price of WAR:BCX is zł88.00. The 52 week high of WAR:BCX is zł98.00 and 52 week low is zł58.90.
When is next earnings date of Bioceltix SA(WAR:BCX)?
The next earnings date of Bioceltix SA(WAR:BCX) is .
Does Bioceltix SA(WAR:BCX) pay dividends? If so, how much?
Bioceltix SA(WAR:BCX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers